NYSE:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis → Does this make you sick? (From Allegiance Gold) (Ad) Free CATX Stock Alerts $1.60 +0.07 (+4.58%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share Today's Range$1.52▼$1.6850-Day Range N/A52-Week Range$0.21▼$1.91Volume5.53 million shsAverage Volume4.23 million shsMarket Capitalization$996.21 millionP/E RatioN/ADividend YieldN/APrice Target$1.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Perspective Therapeutics alerts: Email Address Perspective Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside18.8% Upside$1.90 Price TargetShort InterestHealthy2.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 20 Articles This WeekInsider TradingAcquiring Shares$57.41 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.10) to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.30 out of 5 starsMedical Sector879th out of 914 stocksSurgical & Medical Instruments Industry98th out of 100 stocks 3.5 Analyst's Opinion Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePerspective Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Perspective Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.91% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 30.30%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CATX. Previous Next 2.5 News and Social Media Coverage News SentimentPerspective Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Perspective Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for CATX on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $57,409,487.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.52% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.10) to ($0.11) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Allegiance GoldDoes this make you sick?The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments.Get your Free Wealth Protection Kit About Perspective TherapeuticsPerspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Read More CATX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CATX Stock News HeadlinesMay 20 at 7:00 AM | globenewswire.comPerspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024May 19 at 3:23 AM | americanbankingnews.comPerspective Therapeutics (NYSEAMERICAN:CATX) Shares Up 6.5%May 17 at 6:05 PM | bizjournals.comGT Medical Technologies acquires cancer treatment subsidiary from Seattle companyMay 17 at 2:14 AM | americanbankingnews.comPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Consensus Recommendation of "Buy" by AnalystsMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)May 15, 2024 | bizjournals.comPerspective Therapeutics sells subsidiary to Arizona companyMay 15, 2024 | investorplace.comCATX Stock Earnings: Perspective Therapeutics Meets EPS for Q1 2024May 15, 2024 | washingtonpost.comPerspective Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 ResultsMay 15, 2024 | americanbankingnews.comPerspective Therapeutics (NYSEAMERICAN:CATX) Research Coverage Started at Royal Bank of CanadaMay 14, 2024 | msn.comRBC Capital Initiates Coverage of Perspective Therapeutics (CATX) with Outperform RecommendationMay 12, 2024 | americanbankingnews.comCantor Fitzgerald Begins Coverage on Perspective Therapeutics (NYSEAMERICAN:CATX)May 10, 2024 | americanbankingnews.comPerspective Therapeutics (NYSEAMERICAN:CATX) Reaches New 1-Year High at $1.90May 10, 2024 | americanbankingnews.comPerspective Therapeutics, Inc. Forecasted to Post FY2024 Earnings of ($0.12) Per Share (NYSEAMERICAN:CATX)May 9, 2024 | msn.comCantor Fitzgerald Initiates Coverage of Perspective Therapeutics (CATX) with Overweight RecommendationMay 3, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming May Investor ConferencesMay 2, 2024 | markets.businessinsider.comThe Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 ExpertsMay 2, 2024 | finance.yahoo.comPerspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comPerspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial ResultsApril 30, 2024 | globenewswire.comPerspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETsApril 8, 2024 | globenewswire.comPerspective Therapeutics to Participate at Upcoming April Investor ConferencesMarch 28, 2024 | globenewswire.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ResultsMarch 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Clinical Success and Strategic PartnershipsMarch 19, 2024 | wsj.comPerspective Therapeutics Inc.March 18, 2024 | msn.comPerspective Therapeutics partners with Bristol Myers for its metastatic melanoma treatment studySee More Headlines Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/19/2024Next Earnings5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:CATX CUSIPN/A CIKN/A Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees116Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,510,000.00 Net Margins-302.70% Pretax Margin-3,379.88% Return on Equity-46.38% Return on Assets-39.17% Debt Debt-to-Equity Ratio0.01 Current Ratio12.98 Quick Ratio1.07 Sales & Book Value Annual Sales$1.43 million Price / Sales696.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.37 per share Price / Book4.32Miscellaneous Outstanding Shares622,630,000Free Float600,712,000Market Cap$996.21 million OptionableN/A Beta1.43 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Johan M. Spoor (Age 52)CEO & Director Comp: $855.78kMr. Jonathan R. Hunt (Age 57)CFO & Co-Principal Financial Officer Comp: $944.35kDr. Markus Puhlmann M.B.A. (Age 58)M.D., Chief Medical Officer Comp: $633.14kMr. Shane CobbExecutive Vice President of OperationsMr. Mark J. Austin CPA (Age 37)VP of Finance, Corporate Controller, Co-Principal Financial, Principal Acc. Officer & Secretary Dr. Michael K. Schultz Ph.D.Chief Science OfficerMr. Andrew BrightExecutive Vice President of BrachytherapyMr. Amos Hedt BAPGradDip, Chief Business Strategy OfficerDr. Frances L. Johnson M.D.Chief Innovation OfficerMr. David Hauser Ph.D.Senior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsAinosNASDAQ:AIMDWBone BiologicsNASDAQ:BBLGWDIH Holding USNASDAQ:DHAIWEnvoy MedicalNASDAQ:COCHWHeart Test LaboratoriesNASDAQ:HSCSWView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 13,089,476 shares on 5/16/2024Ownership: 2.230%Affinity Asset Advisors LLCBought 5,100,000 shares on 5/15/2024Ownership: 0.869%Baker BROS. Advisors LPSold 7,489,916 shares on 5/15/2024Ownership: 0.026%Vanguard Group Inc.Bought 4,566,356 shares on 5/10/2024Ownership: 3.029%Bleakley Financial Group LLCBought 33,570 shares on 5/8/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions CATX Stock Analysis - Frequently Asked Questions Should I buy or sell Perspective Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perspective Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CATX shares. View CATX analyst ratings or view top-rated stocks. What is Perspective Therapeutics' stock price target for 2024? 6 analysts have issued twelve-month price objectives for Perspective Therapeutics' stock. Their CATX share price targets range from $1.40 to $3.00. On average, they anticipate the company's share price to reach $1.90 in the next year. This suggests a possible upside of 18.8% from the stock's current price. View analysts price targets for CATX or view top-rated stocks among Wall Street analysts. How have CATX shares performed in 2024? Perspective Therapeutics' stock was trading at $1.19 on January 1st, 2024. Since then, CATX shares have increased by 34.5% and is now trading at $1.60. View the best growth stocks for 2024 here. Are investors shorting Perspective Therapeutics? Perspective Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 13,590,000 shares, an increase of 30.3% from the April 15th total of 10,430,000 shares. Based on an average daily trading volume, of 4,400,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 2.9% of the shares of the stock are short sold. View Perspective Therapeutics' Short Interest. Who are Perspective Therapeutics' major shareholders? Perspective Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.03%), Janus Henderson Group PLC (2.23%), Affinity Asset Advisors LLC (0.87%), Baker BROS. Advisors LP (0.03%), RIA Advisory Group LLC (0.02%) and Simplicity Wealth LLC (0.01%). Insiders that own company stock include Jonathan Robert Hunt, Lantheus Alpha Therapy, Llc, Markus Puhlmann and Robert F Williamson III. View institutional ownership trends. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CATX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
